Gradalis Pushes Back shRNA Rx Trial to Evaluate Delivery, Expression Tech

According to a company official, after having tested the drug's delivery vehicle and expression plasmid separately in humans with gene therapies, Gradalis is now on track to file an investigational new drug application for the shRNA treatment later this year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.